TSO3 Receives 2017 Purchase Orders from Getinge

Backlog for the STERIZONE® VP4 Sterilizer Exceeds $18 Million
QUÉBEC CITY, Dec. 2, 2016 / - TSO3 Inc. (TSX:TOS.TO - News) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, has received initial purchase orders from Getinge USA, Inc., for fiscal 2017. These orders will increase the rate of production and throughput from the Company's assembly facility in Quebec throughout 2017.
The purchase orders were received in association with the distribution agreement signed with Getinge in November 2015.
"This PO from Getinge provides a degree of operational predictability for 2017 as it enables TSO3 to leverage supply chain improvements achieved in fiscal 2016," said R.M. (Ric) Rumble, TSO3's President and CEO. "We look forward to further collaboration and success as we enter our second year of this strategic partnership. TSO3, together with Getinge continue to collaborate and deploy an increasing number of sterilizers and deliver on our vision – Creating the Improved Standard in Healthcare Sterile Reprocessing™."
Read more: TSO3 Inc ( TOS )

Neovasc and Boston Scientific Reach US$75 Million Agreement

- Boston Scientific acquires tissue processing capabilities and takes equity stake in Neovasc -
VANCOUVER, Dec. 2, 2016 - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News) (TSX:NVC.TO - News) today announced that Boston Scientific Corporation (NYSE:BSX - News), a global medical technology leader, has agreed to acquire Neovasc's tissue processing technology and facility for approximately US$67,909,800. Concurrently, Boston Scientific has committed to invest an additional US$7,090,200 in Neovasc for a 15% equity interest in the Company.
"Boston Scientific has been a long-term customer of Neovasc, having historically represented a sizeable percentage of our tissue processing revenues," commented Neovasc CEO, Alexei Marko. "As one of the world's premier device companies, with a global cardio-vascular franchise, this investment in Neovasc enables continued development of our lead products, Reducer and Tiara, and strengthens our resolve to revolutionize how structural heart disease is treated."
Under the terms of the equity investment, Boston Scientific has agreed to purchase 11,817,000 common shares in the capital of Neovasc (the "Common Shares") at a price of US$0.60 per Common Share, for gross proceeds of US$7,090,200, subject to required regulatory approvals, including approval of the Toronto Stock Exchange.
Read more: Neovasc Inc ( NVC / NVCN )

Skyline Medical Receives Health Canada Approval to Market STREAMWAY® System

MINNEAPOLIS, Nov. 22, 2016  -- Skyline Medical Inc. (SKLN) (“Skyline” or “the Company”), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, announces that it has received a Medical Device Establishment License to sell the STREAMWAY System and related disposables in Canada.
A number of distributors have expressed interest in selling STREAMWAY into Canada’s healthcare system.  Skyline has now begun talks with several of them and expects within the next few weeks to come to terms with one or more distributors, covering approximately 1,500 hospitals in all 13 provinces of Canada.
Read more: Skyline Medical Inc ( SKLN )

Medigus Expands Global Commercial Availability of MUSE™ Through Distribution Agreement With INNOVAMEDICA S.p.A. In Italy; New agreement broadens Medigus’ accessibility in key markets around the world

OMER, Israel, Nov. 22, 2016  -- Medigus Ltd. (MDGS) (MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced a distribution agreement in Italy with INNOVAMEDICA S.p.A, a privately owned distributor of minimally invasive medical devices. Under terms of the four-year agreement which will take effect January 1st 2017, INNOVAMEDICA S.p.A. will be required to purchase at least 1M € of Medigus Ultrasonic Surgical Endostapler (MUSE™) equipment over the course of the agreement.
Read more: Medigus Ltd ( MDGS )

Intersect ENT Reports Third Quarter 2016 Results

MENLO PARK, Calif.-- Intersect ENT, Inc. (XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2016.
Third quarter 2016 revenue was $18.5 million, representing a 30% increase over the third quarter 2015.
Third quarter 2016 gross margin was 85% compared to 80% in the third quarter 2015.
Key recent highlights include:
Reporting of positive topline results of the RESOLVE II clinical study. The study met both primary efficacy endpoints: reduction in nasal congestion and polyp burden. RESOLVE II, a 300-patient randomized, blinded, multi-center clinical trial, evaluated the placement of the investigational RESOLVE steroid releasing implant in the physician’s office.
Read more: Intersect ENT Inc ( XENT )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker